Clinical laboratory · 2026
Secondary B-Cell Acute Lymphoblastic Leukemia Following Multiple Myeloma Treatment.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Dongmei, Yang Xiaofeng, Li Shuang, Yang Xiwen, Zhang Ying
Аннотация
BACKGROUND: Secondary B-cell acute lymphoblastic leukemia (B-ALL) following multiple myeloma (MM) is rare.
METHODS AND RESULTS: Our case presents a patient with non-secretory MM, using bortezomib-based induction, autologous transplantation, and sequential Lenalidomide maintenance treatment and persistent complete remission (CR) for about 5 years. Then the patient got secondary B-ALL.
CONCLUSIONS: Autologous stem cell transplant with bortezomib therapy has achieved CR of patients with MM, but also has an increased risk of secondary B-ALL.
METHODS AND RESULTS: Our case presents a patient with non-secretory MM, using bortezomib-based induction, autologous transplantation, and sequential Lenalidomide maintenance treatment and persistent complete remission (CR) for about 5 years. Then the patient got secondary B-ALL.
CONCLUSIONS: Autologous stem cell transplant with bortezomib therapy has achieved CR of patients with MM, but also has an increased risk of secondary B-ALL.
Предметные рубрики MeSH
HumansMultiple MyelomaBortezomibPyrazinesBoronic AcidsLenalidomideThalidomideTransplantation, AutologousRemission InductionMaleAntineoplastic Combined Chemotherapy ProtocolsNeoplasms, Second PrimaryPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma